| Year |
Citation |
Score |
| 2020 |
Jayaraman S, Hou X, Kuffel MJ, Suman VJ, Hoskin TL, Reinicke KE, Monroe DG, Kalari KR, Tang X, Zeldenrust MA, Cheng J, Bruinsma ES, Buhrow SA, McGovern RM, Safgren SL, et al. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research : Bcr. 22: 51. PMID 32430040 DOI: 10.1186/S13058-020-01286-7 |
0.434 |
|
| 2014 |
Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM. Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparative in vivo activity studies Cancer Chemotherapy and Pharmacology. 74: 1271-1278. PMID 25318936 DOI: 10.1007/S00280-014-2605-7 |
0.374 |
|
| 2014 |
Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, et al. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxidants & Redox Signaling. 21: 237-50. PMID 24512128 DOI: 10.1089/Ars.2013.5462 |
0.65 |
|
| 2013 |
Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, et al. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Molecular Cancer Therapeutics. 12: 2110-2120. PMID 23883585 DOI: 10.1158/1535-7163.Mct-12-0962 |
0.673 |
|
| 2013 |
Goetz M, Kuffel M, Reinicke K, Huang Z, Bode A, Cheng J, Hoskin T, Suman V, Artega C, Reid J, Hawse J, Ames M. Abstract P5-09-08: A comparison of the non-genomic effects of endoxifen and tamoxifen in aromatase inhibitor resistant breast cancer: Differential effects on the estrogen receptor co-regulator SRC3 (AIB1) and identification of PKC and PI3K as endoxifen substrates Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-09-08 |
0.396 |
|
| 2012 |
Safgren SL, Buhrow SA, Walden C, Kuffel MJ, Reinicke KE, Reid JM, Goetz MP, Ames MM. Abstract 3781: Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparativein vivoactivity studies Cancer Research. 72: 3781-3781. DOI: 10.1158/1538-7445.Am2012-3781 |
0.346 |
|
| 2011 |
Reinicke KE, Hou X, Goetz MP, Suman VJ, Kuffel MJ, Haluska P, Reid JM, Ames MM. Abstract 2283: Endoxifen exhibits potentin vitroandin vivoantitumor activity in ER+/HER2+ breast cancer and tamoxifen refractory tumors Cancer Research. 71: 2283-2283. DOI: 10.1158/1538-7445.Am2011-2283 |
0.448 |
|
| 2011 |
Goetz M, Hou X, Suman V, Reinicke K, Kuffel M, Haluska P, Oberg A, Grill D, Reid J, Brodie A, Ingle J, Ames M. PD01-06: Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd01-06 |
0.318 |
|
| 2010 |
Reinicke KE, Kuffel MJ, Goetz MP, Ames MM. Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemotherapy and Pharmacology. 66: 575-83. PMID 20012292 DOI: 10.1007/S00280-009-1198-Z |
0.53 |
|
| 2009 |
Goetz M, Reinicke K, Reid J, Suman V, Kuffel M, Safgren S, Buhrow S, Reynolds C, Jenkins R, Hawse J, Perez E, Ingle J, Ames M. Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+ Breast Cancer. Cancer Research. 69: 2006-2006. DOI: 10.1158/0008-5472.Sabcs-09-2006 |
0.421 |
|
| 2007 |
Bentle MS, Reinicke KE, Dong Y, Bey EA, Boothman DA. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Research. 67: 6936-45. PMID 17638905 DOI: 10.1158/0008-5472.Can-07-0935 |
0.66 |
|
| 2007 |
Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone Proceedings of the National Academy of Sciences of the United States of America. 104: 11832-11837. PMID 17609380 DOI: 10.1073/Pnas.0702176104 |
0.662 |
|
| 2006 |
Bey EA, Wuerzberger-Davis SM, Pink JJ, Yang CR, Araki S, Reinicke KE, Bentle MS, Dong Y, Cataldo E, Criswell TL, Wagner MW, Li L, Gao J, Boothman DA. Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses. Journal of Cellular Physiology. 209: 604-10. PMID 17001694 DOI: 10.1002/Jcp.20783 |
0.614 |
|
| 2006 |
Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. The Journal of Biological Chemistry. 281: 33684-96. PMID 16920718 DOI: 10.1074/Jbc.M603678200 |
0.637 |
|
| 2006 |
Bentle MS, Bey EA, Dong Y, Reinicke KE, Boothman DA. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. Journal of Molecular Histology. 37: 203-18. PMID 16868862 DOI: 10.1007/S10735-006-9043-8 |
0.567 |
|
| 2005 |
Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, Misico RI, Arzac GM, Burton G, Bornmann WG, Sutton D, Gao J, Boothman DA. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3055-64. PMID 15837761 DOI: 10.1158/1078-0432.Ccr-04-2185 |
0.625 |
|
| 2005 |
Araki S, Israel S, Leskov KS, Criswell TL, Beman M, Klokov DY, Sampalth L, Reinicke KE, Cataldo E, Mayo LD, Boothman DA. Clusterin proteins: stress-inducible polypeptides with proposed functions in multiple organ dysfunction British Journal of Radiology. 106-113. DOI: 10.1259/Bjr/18105113 |
0.573 |
|
| 2003 |
Tagliarino C, Pink JJ, Reinicke KE, Simmers SM, Wuerzberger-Davis SM, Boothman DA. Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biology & Therapy. 2: 141-52. PMID 12750552 DOI: 10.4161/Cbt.2.2.237 |
0.658 |
|
| Show low-probability matches. |